BIIB 113
Alternative Names: BIIB-113Latest Information Update: 28 Jul 2023
At a glance
- Originator Biogen
- Class Antidementias; Small molecules
- Mechanism of Action Hexosaminidase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 08 Jun 2023 Biogen completes phase I trial in Alzheimer's disease (In volunteers) in United Kingdom and Sweden (PO) (NCT05195008)
- 30 Apr 2023 Biogen initiates a phase I pharmacokinetic trial in Healthy volunteers in United Kingdom (PO) (ISRCTN48011192)
- 24 Jan 2022 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Sweden (PO) (NCT05195008)